CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Increase in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 338,700 shares, an increase of 88.1% from the March 15th total of 180,100 shares. Approximately 11.6% of the company’s shares are sold short. Based on an average daily trading volume, of 634,900 shares, the short-interest ratio is currently 0.5 days.

Institutional Investors Weigh In On CNS Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CNSP. Jane Street Group LLC grew its stake in shares of CNS Pharmaceuticals by 1,712.3% during the 4th quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock worth $51,000 after acquiring an additional 396,577 shares in the last quarter. Citadel Advisors LLC bought a new position in CNS Pharmaceuticals in the fourth quarter valued at $39,000. XTX Topco Ltd acquired a new stake in CNS Pharmaceuticals in the 4th quarter valued at $36,000. Connective Capital Management LLC bought a new stake in CNS Pharmaceuticals during the 4th quarter worth about $34,000. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of CNS Pharmaceuticals during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

CNS Pharmaceuticals Stock Performance

NASDAQ CNSP traded down $0.00 on Thursday, reaching $0.82. The company had a trading volume of 172,516 shares, compared to its average volume of 288,127. The company’s fifty day moving average is $2.72 and its 200-day moving average is $4.70. CNS Pharmaceuticals has a 1-year low of $0.77 and a 1-year high of $800.00. The firm has a market capitalization of $2.41 million, a price-to-earnings ratio of -0.01 and a beta of 2.72.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CNSP shares. Maxim Group reissued a “hold” rating on shares of CNS Pharmaceuticals in a research note on Tuesday, March 25th. Alliance Global Partners upgraded CNS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 24th.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.